Navigation Links
Patient's own immune cells may blunt viral therapy for brain cancer

  • People with a type of brain tumor called glioblastoma live 12 months on average, so new forms of treatment for this malignancy are badly needed.
  • Viruses designed to kill cancer cells offer a safe way to treat these tumors, but the therapy doesn't work as well as expected.
  • This study found that a patient's immune system tries to eliminate the anticancer virus and blocking this immune activity gave the virus more time to kill cancer cells.

COLUMBUS, Ohio Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected.

A new study led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) shows that the reason for this is in part due to the patient's own immune system, which quickly works to eliminate the anticancer virus.

The findings, published in the journal Nature Medicine, show that the body responds to the anticancer virus as it does to an infection. Within hours, specialized immune cells called natural killer (NK) cells move in to eliminate the therapeutic virus in the brain.

The researchers discovered that the NK cells attack the viruses when they express specific molecules on their surface called NKp30 and NKp46. "These receptor molecules enable the NK cells to recognize and destroy the anticancer viruses before the viruses can destroy the tumor," says co-senior author Dr. Michael A. Caligiuri, director of Ohio State's Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute, and a senior author of the study.

"When we blocked those receptors, the virus has more time to work, and mice with these brain tumors live longer. The next step is to block these molecules on NK cells in glioblastoma patients and see if we can improve their outcome," says Caligiuri, who is also the John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research. This study of cancer-cell-killing, or oncolytic, viruses is an example of the value of translational research, in which a problem observed during clinical trials is studied in the laboratory to devise a solution.

"In this case, clinical trials of oncolytic viruses proved safe for use in the brain, but we noticed substantial numbers of immune cells in brain tumors after treatment," says senior author and neurosurgeon Dr. E. Antonio Chiocca, who was professor and chair of neurological surgery while at Ohio State University.

"To understand this process, we went back to the laboratory and showed that NK cells rapidly infiltrate tumors in mice that have been treated with the therapeutic virus. These NK cells also signal other inflammatory cells to come in and destroy the cancer-killing virus in the tumor."

The study used an oncolytic herpes simplex virus, human glioblastoma tumor tissue and mouse models, one of which hosted both human glioblastoma cells and human NK cells. Key technical findings include:

  • Replication of the therapeutic virus in tumor cells in an animal model rapidly attracted subsets of NK cells to the tumor site;
  • NK cells in tumors activated other immune cells (i.e., macrophages and microglia) that have both antiviral and anticancer properties;
  • Depletion of NK cells improves the survival of tumor-bearing mice treated with the therapeutic virus;
  • NK cells that destroy virus-infected tumor cells express the NKp30 and NKp46 receptors molecules that recognize the virus.

"Once we identify the molecules on glioblastoma cells that these NK cell receptors bind with, we might be able to use them to identify patients who will be sensitive to this therapy," Caligiuri says.

Contact: Darrell E. Ward
Ohio State University Medical Center

Related medicine news :

1. New drug overcomes resistance in patients with rare sarcoma
2. First patients in US receive non-surgical device of sunken chest syndrome
3. Patients Balk at Asking Health Care Workers to Wash Hands
4. Scans Spot Brain Changes in Patients With Concussion Syndrome
5. MRI shows brain disruption in patients with post-concussion syndrome
6. GHSU researcher assesses driving capability in MS patients
7. Costly, Repeat Medical Testing Common for Medicare Patients: Study
8. Uninsured patients undergoing craniotomy for brain tumor have higher in-hospital mortality
9. Many Surgical Complications Occur After Patients Go Home
10. New study review examines benefits of music therapy for surgery patients
11. New tumor tracking technique may improve outcomes for lung cancer patients
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort to ... to access life-saving information provided directly from top experts in mesothelioma, in 2016 ... conferences in three major cities: Houston, San Francisco, and Chicago. , “For ...
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... hunger cravings that drive people to overeat are not necessarily caused by real hunger, ... brain that the stomach needs food. He notes that, while many patients are aware ...
(Date:11/30/2015)... FL (PRWEB) , ... November 30, 2015 , ... ... a comparison chart and ingredient list of its hemorrhoid ointment to its website. ... effective pain relief for people suffering from hemorrhoids. Adding the comparison chart and ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood sugar tests ... adults, according to a new study by researchers at the School of Public Health ... Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published 32nd Annual ... (NPDS) reveals that in 2014, someone called a poison center about every 11 ... which were human exposure cases. , The American Association of Poison Control Centers ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Medical Systems (NYSE: VAR ) has signed a Memorandum of ... the largest hospital chain in India , to ... country. The MoU was signed by Dr. K. Prabakar , ... Varian,s India managing director, in ... intends to deploy its Access to Care program by leveraging the ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
(Date:11/30/2015)... -- Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare ... , a country of over 122 million people. --> ... million people. --> It offers companies, investors, policymakers, and ... into the second largest pharma and healthcare market in ...
Breaking Medicine Technology: